Population pharmacokinetics of belimumab following intravenous administration in patients with systemic lupus erythematosus

Journal of Clinical Pharmacology

Volumn 53, Issue 7, 2013, Pages 711-720

  Struemper, Herbert ^a   Chen, Cecil ^a   Cai, Wendy ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Belimumab; Pharmacokinetics; Systemic lupus erythematosus

Indexed keywords

BELIMUMAB;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY MASS; BODY SIZE; BODY WEIGHT; COMPARTMENT MODEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EXPOSURE; DRUG HALF LIFE; FEMALE; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROTEIN URINE LEVEL; PROTEINURIA; STEADY STATE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADMINISTRATION, INTRAVENOUS; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; AREA UNDER CURVE; BODY WEIGHT; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; FEMALE; HALF-LIFE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE;

EID: 84880261761     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.104     Document Type: Article

References (26)

1. Cancro MP, D'Cruz DP, Khamashta MA. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest. 2009;119:1066-1073.
2. Bosello S, Youinou P, Daridon C, et al. Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis. J Rheumatol. 2008;35:1256-1264.
3. Cheema GS, Roschke V, Hilbert DM, et al. Elevated serum B lymphocyte stimulator levels in patients with systemic immunebased rheumatic diseases. Arthritis Rheum. 2001;44:1313-1319.
4. Emmerich F, Bal G, Barakat A, et al. High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura. Br J Haematol. 2007;136: 309-314.
5. Groom J, Kalled SL, Cutler AH, et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J Clin Invest. 2002;109:59-68.
6. Petri M, Stohl W, Chatham W, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum. 2008;58:2453-2459.
7. Sanders JS, Huitma MG, Kallenberg CG, Stegeman CA. Plasma levels of soluble interleukin 2 receptor, soluble CD30, interleukin 10 and B cell activator of the tumour necrosis factor family during follow-up in vasculitis associated with proteinase 3-antineutrophil cytoplasmic antibodies: associations with disease activity and relapse. Ann Rheum Dis. 2006;65:1484-1489.
8. Schneeweis C, Rafalowicz M, Feist E, et al. Increased levels of BLyS and sVCAM-1 in anti-neutrophil cytoplasmatic antibody (ANCA)-associated vasculitides (AAV). Clin Exp Rheumatol. 2010;28(1 suppl):62-66.
9. Zhang J, Roschke V, Baker K, et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol. 2001;166:6-10.
10. Baker KP, Edwards BM, Main SH, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 2003;48:3253-3265.
11. Halpern WG, Lappin P, Zanardi T, et al. Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects. Toxicol Sci. 2006;91:586-599.
12. Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebocontrolled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63:3918-3930.
13. Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled phase 3 trial. Lancet. 2011;377: 721-731.
14. Furie R, Stohl W, Ginzler EM, et al. Belimumab Study Group. Biologic activity and safety of belimumab, a neutralizing anti-Blymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther. 2008;10:R109.
15. Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009;61:1168-1178.
16. Fast DM, Kelley M, Viswanathan CT, et al. Workshop report and follow-up -AAPS workshop on current topics in GLP bioanalysis: assay reproducibility for incurred samples -implications of crystal city recommendations. AAPS J 2009;11:238-241.
17. Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49: 633-659.
18. Raison J, Achimastos A, Bouthier J, London G, Safar M. Intravascular volume, extracellular fluid volume, and total body water in obese and nonobese hypertensive patients. Am J Cardiol. 1983;51:165-170.
19. Kim K-J, Fandy TE, Lee VHL, et al. Net absorption of IgG via FcRn mediated transcytosis across rat alveolar epithelial cell monolayers. Am J Physiol Lung Cell Mol Physiol. 2004;287:616-622.
20. HUMIRA(adalimumab). Full Prescribing Information. North Chicago, IL: Abbott Laboratories; 2012.
21. REMICADE (infliximab). Full Prescribing Information. Horsham, PA: Janssen Biotech, Inc.; 2011.
22. SIMPONI (golimumab). Full prescribing information Horsham, PA: Janssen Biotech, Inc., August 2011.
23. Schmitt C, Kuhn B, Zhang X, et al. Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clin Pharmacol Ther. 2011;89:735-740.
24. Roopenian DC, Sun VZ. Clinical ramifications of the MHC family Fc receptor FcRn. J Clin Immunol. 2010;30:790-797.
25. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharm Ther. 2008 84:548-558.
26. Mager DE, Jusko JJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001;28:507-532.